Maximizing antimalarial efficacy and the importance of dosing strategies

BMC Medicine

Freya JI Fowkes¹  Philippe Boeuf¹  James G Beeson¹ 

[1] Burnet Institute, 85 Commercial Road, Melbourne 3004, Victoria, Australia

关键词: Malaria;    Drug resistance;    Artesunate;    Artemisinins;    Amodiaquine;   

Others  :  1203888
DOI  :  10.1186/s12916-015-0349-9

 received in 2015-04-16, accepted in 2015-04-16,  发布年份 2015

【 摘 要 】

Artemisinin-based combination therapies (ACTs) are the cornerstone for the treatment of malaria. However, confirmed resistance to artemisinins in South-East Asia, and reports of reduced efficacy of ACTs raise major concerns for malaria treatment and control. Without new drugs to replace artemisinins, it is essential to define dosing strategies that maximize therapeutic efficacy, limit the spread of resistance, and preserve the clinical value of ACTs. It is important to determine the extent to which reduced efficacy of ACTs reflects true resistance versus sub-optimal dosing, and quantify other factors that determine treatment failure. Pooled analyses of individual patient data from multiple clinical trials, by investigators in the Worldwide Antimalarial Resistance Network, have shown high overall efficacy for three widely used ACTs, artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine. Analyses also highlight that suboptimal dosing leads to increased risk of treatment failure, especially among children. In the most recent study, an analysis of clinical trials of artesunate-amodiaquine, widely used among children in Africa, revealed a superior efficacy for fixed-dose combination tablets compared to loose non-fixed dose combinations. This highlights the benefits of fixed-dose combinations as a practical strategy for ensuring optimal antimalarial dosing and maximizing efficacy.

Please see related article: http://www.biomedcentral.com/1741-7015/13/66 webcite

【 授权许可】

   
2015 Beeson et al.; licensee BioMed Central.

【 参考文献 】

• [1]Guidelines for the treatment of malaria. 2nd ed. World Health Organisation, Geneva; 2010.
• [2]World malaria report 2014. World Health Organisation, Geneva; 2014.
• [3]Worldwide Antimalarial Resistance Network ALDISG. The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infect Dis. 2015. Ahead of print.
• [4]Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S et al.. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014; 371:411-23.
• [5]Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J et al.. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361:455-67.
• [6]Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N et al.. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014; 505:50-5.
• [7]Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP et al.. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015; 347:428-31.
• [8]Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T et al.. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015; 347:431-5.
• [9]Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T et al.. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015; 15:415-21.
• [10]Rwagacondo CE, Karema C, Mugisha V, Erhart A, Dujardin JC, Van Overmeir C et al.. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health. 2004; 9:1091-8.
• [11]Bonnet M, Broek I, van Herp M, Urrutia PP, van Overmeir C, Kyomuhendo J et al.. Varying efficacy of artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. Malar J. 2009; 8:192. BioMed Central Full Text
• [12]Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C et al.. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005; 365:1474-80.
• [13]Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M et al.. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 2002; 359:1365-72.
• [14]Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP et al.. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010; 10:673-81.
• [15]Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R et al.. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007; 44:1067-74.
• [16]Worldwide Antimalarial Resistance Network AS-AQ Study Group. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 2015;13:66.
• [17]Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM et al.. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015; 211:680-8.
• [18]Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H et al.. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009; 8:203. BioMed Central Full Text
• [19]Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:e1001119.
• [20]Thanh NX, Trung TN, Phong NC, Quang HH, Dai B, Shanks GD et al.. The efficacy and tolerability of artemisinin-piperaquine (Artequick(R)) versus artesunate-amodiaquine (Coarsucam) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malar J. 2012; 11:217. BioMed Central Full Text
• [21]Sirima SB, Tiono AB, Gansane A, Diarra A, Ouedraogo A, Konate AT et al.. The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malar J. 2009; 8:48. BioMed Central Full Text
• [22]Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M et al.. Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop Med Int Health. 2009; 14:79-87.
• [23]Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y et al.. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001; 344:257-63.
• [24]Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002; 298:210-3.
• [25]Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C et al.. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014; 91:833-43.
• [26]Worldwide Antimalarial Resistance Network DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10:e1001564; discussion e1001564.